1

PRODUCTION OF
AFFORDABLE CHEMOTHERAPY
M. Sjamsul Arifin
President Director of PT. Kimia Farma. Tbk
2 AGENDA ….
1. GLOBAL CANCER MARKET
2. INDONESIAN PHARMA MARKET
3. KF EFFORT
4. SUMMARY
 GLOBAL CANCER ……..

Market Size: 65 billion USD

Growth Rate: 23%
Third biggest therapy class
Out of 82 blockbuster drugs 7
are anticancer*

*MabThera, Glivec, Eloxatin, Gemzar, Casodex, Taxotere & Zometa

3 Source: Business Wire – , 2008 – IMS Health

 CANCER INCIDENCE GLOBALLY ….
4

18,30% 17,90%

14,60%
12,20% 11,50%

5,50% 5,20%
3,60% 3,40%
2,30% 2,20% 1,80% 1,60%
 TOP 5 CANCERS GLOBALLY BY GENDER …..
TOP 5 IN FEMALES

Breast 36.70%

Large Bowel 17.30%

Melanoma of
Skin 11.40%

TOP 5 IN MALES Lung 8.90%

Non Hodgkins
Prostate 29.20% Lymphoma 0.10%

Large Bowel 18.50%

Lung 14.10%

Melanoma of
Skin 12.90%

Non Hodgkins
Lymphoma 4.90%

5
 UNIQUE THERAPHY BEHAVIOUR ……..

Note : 50% of growth is driven by New Drugs

6
7 INDONESIAN PHARMA MARKET ….
8
9
 MARKET ANALYSIS ( Cancer Product ) …
10

Value : IDR Billions

RANK COMPANY 2008 G% 2007 G% 2006

1 LC 144 (7.7) 156 21.4 156

2 MNC 78 35.2 58 31.9 44

3 MNC 43 5.9 40 52.9 27

4 LC 28 36.8 20 32.7 15

5 LC 27 4.2 26 11.2 23

6 MNC 25 (7.9 ) 28 10.9 25

Based on ITMA Data MAT Dec 2008

 KF as a state Own Company …
11

¨ We have business from down stream to up stream :

¤ 5 Manufacturers
¤ 40 distributors

¤ 350 retail pharmacies

¤ 500 Medical representative

¨ We also have many range of products & to serve

many customers ( private sector & government sector )
 KF EFFORT ….
12

q KF will develop strategic products for Cancer & HIV

AIDS
q KF will cooperation with national Insurance & Cancer
Hospital
q KF will have a collaboration with:
q Domestic Partner : BATAN
q Foreign Partner : Naprod & 3M
q In future KF will build a Plant for developing Cancer
& HIV products (already finished)
13 Prevention Cancer Therapeutics
1. Early Detection and Screening
2. Diagnosis and Treatment
3. Support and Rehabilitation
4. Palliative Care
 14

STRATEGYC PRODUCT FOR CANCER

 LIST PRODUCT ONCOLOGY BY KF (NAPROD) ……..
No. Product Name Active Pharma Ing Strenght Pack size
1 Napro-Tax Paclitaxel 30 mg 6 mg/ ml vial 5 ml
2 Cisteen Cisplatin 10 mg 1 mg / ml vial 10 ml
3 Cisteen Cisplatin 50 mg 1 mg / ml vial 50 ml
4 Alltrex Methotrexate 50 mg 25 mg /ml vial 2 ml
5 Alltrex Methotrexate 2.5 mg tablet 2.5 mg 100 tab
6 Naprocil 5 - Fluourouracil 500 mg 100 mg / ml vial 10 mg
7 Naprodox Doxorubicin 10 mg 2 mg / ml vial 5 ml
8 Naprodox Doxorubicin 50 mg 2 mg / ml vial 25 ml
9 Nzytop Etoposide 100 mg 20 mg / ml vial 5 ml
10 Xifen Tamoxifen 10 mg 10 mg / capsul 10 x 10 cap
11 Xifen Tamoxifen 20 mg 20 mg / capsul 10 x 10 cap
12 Cyclophosphamidie 500 mg vial
13 Taceedo Docitaxel 20 mg vial
14 Taceedo Docitaxel 80 mg vial
15 4-Epeedo-10 Epirubicin 10 mg vial
16 4-Epeedo-50 Epirubicin 50 mg vial
17 Abingem – 200 Gemcitabine inj 200 mg vial
15
18 Abingem – 1 Gr Gemcitabine inj 1.000 mg vial
16
17
 To Produce Affordable Price
18

¨ To make copy product

¤ Cooperation with Naprod (specialist oncology product)
¤ 18 SKU product chemoterapy

¤ Saving Cost ( 20 % – 50 % EP )

¨ Easy to get and avalailable in all provinces

¨ Quality guaranteed
 Price
Ingredient Brand Name Company Price

C
Ratio (%)
4-Epeedo-10 Naprod 185.000 80
Epirubicin 10 mg Epirubicin Kompetitor 230.000 100

P O
M
Epirubicin 50 mg

Docetaxel 20 mg
4-Epeedo-50
Epirubicin

Taceedo 20
Taxotere
Naprod
Kompetitor

Naprod
Kompetitor A
900.000
1.130.000

1.100.000
2.250.830
80
100

49/79
100
Brexel Kompetitor B 1.400.000 100

R P
A
Docetaxel 80 mg
Taceedo 80
Taxotere
Brexel
Naprod
Kompetitor A
Kompetitor B
3.500.000
6.941.780
4.300.000
50/81
100
100

Napro-Tax 30 mg Naprod 700.000 52/72

I
Taxol Kompetitor A 1.334.800 100

R Paclitaxel 30 mg
Paxus

Naprodox 10 mg
Kompetitor B

Naprod
907.500

120.000
100

78

A Doxorubicin 10 mg Doxorubicin Kompetitor A 154.000 100

C
Naprodox 50 mg Naprod 550.000 79

T Doxorubicin 80 mg Doxorubicin

Abingem 200
Kompetitor A

Naprod
696.850

500.000
100

81
Gemzar Kompetitor A 617.272 100
I
Gemcitabin 200 mg

E
Abingem 1 gr Naprod 2.400.000 82
Gemcitabin 1 g Gemzar Kompetitor A 2.935.545 100

V Cisplatin 10 mg
Cisteen 10 mg
Cisplatin
Naprod
Kompetitor A
50.000
69.300
72
100

E Cisplatin 50 mg
Cisteen 50 mg
Cisplatin
Naprod
Kompetitor A
215.000
290.000
74
100
19
 RATIONAL DRUG USE (WHO 2001)
20

q Patients receive medicines appropriate to their

clinical needs
q Doses that meet their individual requirement.
q For an adequate period of time
q The lowest cost to them and their community
21
 WHAT IS ….BIO-EQUIVALENT
22
 GENERIC DRUG SUBSTITUTE REQUIREMENT …
23

Source : FDA Division of Bioequivalence

 To Conduct Sinergy ….
24

¨ To support & supply government needs for Social

Health Insurance
¨ To make co-operation with National Health
Insurance
¨ Co-operation with Cancer Hospital
¨ Mutual benefit for government, health insurance
corporate, hospitals and public to complete cancer
treatments
25 SUMMARY …..
q KF committed to launch chemotherapy product
& affordable price
q KF committed to assist government health

program
q Sinergy program with governmet, health

insurance , hospitals for implementing of

integrated cancer treatment
TEAM WORK …. ????
27 Thank You ….